Clinical trial NCT06987318: A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection
Official title: A Phase I Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
Conditions: HIV-1-infection
Keywords: Suppressive Antiretroviral Therapy
Acute HIV-1
Broadly neutralizing antibody
Antibodies
HIV
HIV antibody
HIV Broadly neutralizing antibody
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Sponsor class: NIH
Collaborators: name: Monogram Biosciences
First posted: 2025-05-23
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Intervention model description: Enrollment will be opened to Arm A first. Once Arm A enrollment is completed, enrollment to Arm B will be opened.
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety, tolerability, and efficacy of combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).

Detailed description: This study is an open-label, two-arm, multi-step phase I study evaluating a combination of two broadly neutralizing antibodies (bNAbs), VRC07-523LS and PGT121.414.LS, in people living with HIV (PWH) who started antiretroviral therapy (ART) during acute/early infection. Participants will receive PGT121.414.LS and VRC07-523LS prior to undergoing an analytical treatment interruption (ATI). Participants will restart ART and continue follow-up after ATI to confirm viral suppression.

Participants will be screened for eligibility and have a pre-entry visit. After determination of eligibility, participants will be enrolled sequentially into Arm A (n=20) and then Arm B (n=20). The study consists of three steps including an analytic treatment interruption.

Arm A:

* Step 1: Participants remain on ART and will receive an infusion of VRC07-523LS and PGT121.414.LS at study entry.
* Step 2: Participants will interrupt their ART and receive a second infusion of VRC07-523LS 12 weeks after the initial infusion. Participants will be monitored closely for indications to resume ART.
* Step 3: Upon meeting ART restart criteria in Step 2; participants will resume ART and be followed for up to 24 weeks.

Arm B:

* Step 1: Participants remain on ART and will receive an infusion of VRC07-523LS and PGT121.414.LS at study entry and a second infusion of VRC07-523LS 12 weeks later.
* Step 2: Participants will interrupt their ART. Participants will be monitored closely for indications to resume ART.
* Step 3: Upon meeting ART restart criteria in Step 2; participants will resume ART and be followed for up to 24 weeks.

Participation in both arms will last up to 98 weeks.

Eligibility criteria: Inclusion Criteria:

* Ability and willingness of participant to provide informed consent.
* Initiation of combination ART within 90 days of acute HIV diagnosis as defined by any of the criteria listed below:

  * A negative HIV Ab or HIV Ag/Ab Combination Assay and a detectable HIV-1 RNA (qualitative or quantitative) or a subsequently positive Western blot (WB) or equivalent HIV-1 confirmatory assay (e.g. Geenius assay) if no positive HIV-1 RNA test was available.
  * A positive HIV Ab or HIV Ag/Ab Combination Assay or p24 antigen test and a negative or indeterminate HIV confirmatory/differentiating test with a detectable HIV-1 RNA (qualitative or quantitative).
  * A positive HIV Ab or HIV-1 RNA or p24 antigen and positive WB or Geenius HIV-1/HIV-2 Supplemental Assay that is negative for p31 band.
  * Two different rapid HIV tests with discordant results followed by subsequently positive HIV serum antibody and/or HIV-1 RNA tests.
  * A positive HIV antibody test according to standard criteria obtained within 60 days after an initial negative or indeterminate HIV antibody, antigen, or nucleic acid amplification.
* For women who are able to become pregnant, negative serum or urine pregnancy test within 48 hours prior to Step 1 entry.
* All study candidates must agree not to participate in an assisted conception process (e.g., sperm donation, intrauterine insemination, in vitro fertilization) from the screening visit until 12 weeks after the final study visit.
* Women who can become pregnant and are engaging in sexual activity that could lead to pregnancy must agree to use one highly effective method of contraception from Step 1 entry until 12 weeks after the final study visit.
* Willingness to use barrier protection (male or female) during sexual activity during ATI and through confirmed viral resuppression.
* Weight ≥50 kg and ≤150 kg at screening.
* On stable suppressive ART for at least 12 months prior to Step 1 entry. No known ART interruption for longer than 14 days within 12 months prior to Step 1 entry. No more than two known ART interruptions of a duration between 14 and 60 consecutive days since initiation of ART.
* ART regimens must contain a protease inhibitor (PI) or integrase strand transfer inhibitor (INSTI) as one of the active drugs in the ART regimen at the time of Step 1 entry.
* CD4+ cell count of \>450 cells/mL obtained within 60 days prior to Step 1 entry.
* Within 60 days prior to Step 1 entry, plasma HIV-1 RNA \< 50 copies/mL of plasma.
* Plasma HIV-1 RNA \<50 copies/mL (or below the assay limit of quantification if the local assay limit of quantification is \>50 copies/mL) since initial viral suppression on ART and for at least 1 year prior to Step 1 entry.
* Willingness to participate in an ATI.
* The following laboratory values obtained within 60 days prior to Step 1 entry:

  * Absolute neutrophil count (ANC) ≥1000 cells/mm\^3
  * Hemoglobin ≥12.0 g/dL for men and ≥11.0 g/dL for women
  * Platelet count ≥125,000/mm\^3
  * Estimated glomerular filtration rate (eGFR) ≥60 mL/min/1.73 m\^2 calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) 2021 equation
  * Total bilirubin \<1.5 x upper limit of normal (ULN)
  * Aspartate aminotransferase (AST) (SGOT) \<1.5 x ULN
  * Alanine aminotransferase (ALT) (SGPT) \<1.5 x ULN
  * Alkaline phosphatase \<1.5 x ULN
* Hepatitis C virus (HCV) antibody negative result within 60 days prior to Step 1 entry or, for participants who are HCV antibody positive (based on testing performed at any time prior to Step 1 entry), a negative HCV RNA result obtained within 60 days prior to Step 1 entry.
* Negative hepatitis B surface antigen (HBsAg) result obtained within 60 days prior to Step 1 entry.
* Ability and willingness to restart ART following ATI according to study guidelines.
* Completion of pre-entry leukapheresis or Large Volume Blood Draw (LVBD).

Exclusion Criteria:

* Breastfeeding or plans to become pregnant within the next 36 months.
* Known allergy/sensitivity or any hypersensitivity to components of study treatment or its formulation.
* Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
* Receipt of any investigational vaccine within 6 months prior to Step 1 entry.
* Receipt of any vaccine within 14 days prior to Step 1 entry.
* Prior receipt of anti-HIV broadly neutralizing antibody therapy.
* Prior receipt of a latency-reversing agent (LRA), whether licensed or investigational, unless reviewed and approved by the study's CMC.
* AIDS-defining illness or opportunistic infection within 24 months prior to Step 1 entry.
* Any clinically significant acute or chronic medical condition (such as autoimmune diseases), other than HIV infection, that in the opinion of the investigator would preclude participation.
* Any history of an HIV-associated malignancy, including Kaposi's sarcoma and any type of lymphoma, or virus-associated cancers.
* History of progressive multifocal leukoencephalopathy (PML).
* Active or recent non-HIV-associated malignancy requiring systemic chemotherapy or surgery within 36 months prior to Step 1 entry or for whom such therapies are expected in the subsequent 12 months.
* Receipt of cabotegravir-LA intramuscular (IM) or rilpivirine-LA IM or lenacapavir (SQ) within 24 months prior to Step 1 entry.
* Resistance to one or more drugs in two or more ARV drug classes.
* History of systemic corticosteroids (long-term use), immunosuppressive anti-cancer or other immunosuppressive agents, interleukins, systemic interferons, systemic chemotherapy, or other medications considered significant by the investigator within the 6 months prior to Step 1 entry.
* History of or current clinical atherosclerotic cardiovascular disease (ASCVD), as defined by 2013 ACC/AHA guidelines, including a previous diagnosis of any of the following:

  * Acute myocardial infarction
  * Acute coronary syndromes
  * Stable or unstable angina
  * Coronary or other arterial revascularization
  * Stroke
  * Transient ischemic attack
  * Peripheral arterial disease presumed to be of atherosclerotic origin
* For participants aged ≥40: 10-year ASCVD risk score estimated by Pooled Cohort Equations \>20% within 60 days prior to Step 1 entry.
* Acute or serious illness requiring systemic treatment and/or hospitalization within 60 days prior to Step 1 entry.

Primary outcomes:
measure: Number of participants experiencing a Grade ≥3 Adverse Event (AE) or Serious Adverse Events (SAE) that are related to VRC07-523LS or PGT121.414.LS
timeFrame: Baseline through 36 weeks after the last dose of study treatment received
measure: Proportion of study participants experiencing viral suppression, defined as HIV-1 RNA <200 copies/mL and remaining off ART
timeFrame: At 62 weeks after Step 1 entry
Secondary outcomes:
measure: Change from Step 1 entry in cell-associated HIV-1 RNA/DNA ratio in total CD4+ cells
timeFrame: Study entry through 72 weeks
measure: Change from Step 1 entry in low-level viremia measured by single copy assay (SCA)
timeFrame: Study entry through 72 weeks
measure: Change from Step 1 entry in levels of intact proviral DNA in CD4+ T-cells
timeFrame: Study entry through 72 weeks
measure: Change from Step 1 entry in levels of inducible infectious virus on CD4+ T-cells
timeFrame: Study entry through 72 weeks
measure: Average number of weeks from ATI until meeting the virologic criteria for ART restart
timeFrame: Week 2 through Week 72
measure: Proportion of participants with HIV-1 RNA<1000 copies/mL
timeFrame: At 62 weeks
measure: Serum concentrations of VRC07-523LS and PGT121.414.LS at the time meeting the virologic criteria for ART restart
timeFrame: At week 72
measure: Area Under the Curve (AUC) of VRC07-523LS and PGT121.414.LS
timeFrame: Week 0 through End of Study, an average of 98 weeks
measure: IC50 for neutralization sensitivity of the HIV-1 envelope population to VRC07-523LS and PGT121.414.LS
timeFrame: Week 0 through Week 72
measure: Proportion of participants who develop antibodies to VRC07-523LS and PGT121.414.LS
timeFrame: Week 0 through End of Study, an average of 98 weeks
measure: CD4+ T-cells counts
timeFrame: Week 0 through End of Study, an average of 98 weeks
measure: HIV-1-specific T-cell count measured by Intracellular Cytokine Staining
timeFrame: Week 0 through Week 72
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: Alabama CRS
state: Alabama
city: San Diego
country: United States
facility: UCSD Antiviral Research Center CRS
state: California
city: Aurora
country: United States
facility: University of Colorado Hospital CRS
state: Colorado
city: Atlanta
country: United States
facility: The Ponce de Leon Center CRS
state: Georgia
city: Chicago
country: United States
facility: Northwestern University CRS
state: Illinois
city: Boston
country: United States
facility: Massachusetts General Hospital CRS (MGH CRS)
state: Massachusetts
city: Chapel Hill
country: United States
facility: Chapel Hill CRS
state: North Carolina
city: Columbus
country: United States
facility: Ohio State University CRS
state: Ohio
city: Philadelphia
country: United States
facility: Penn Therapeutics CRS
state: Pennsylvania
city: Houston
country: United States
facility: Houston Advancing Research Team CRS
state: Texas
city: Porto Alegre
country: Brazil
facility: Instituto de Pesquisas em AIDS do Rio Grande do Sul - IPARGS CRS
state: Rio Grande Do Sul
city: Rio De Janeiro
country: Brazil
facility: Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
city: Lima
country: Peru
facility: Barranco CRS
Study officials:
References: